151 related articles for article (PubMed ID: 21585222)
1. Risk of depressive episodes with rimonabant: a before and after modified prescription event monitoring study conducted in England.
Buggy Y; Cornelius V; Wilton L; Shakir SA
Drug Saf; 2011 Jun; 34(6):501-9. PubMed ID: 21585222
[TBL] [Abstract][Full Text] [Related]
2. Reasons for and time to discontinuation of rimonabant therapy: a modified prescription-event monitoring study.
Willemen MJ; Mantel-Teeuwisse AK; Buggy Y; Layton D; Straus SM; Leufkens HG; Egberts TC
Drug Saf; 2012 Dec; 35(12):1147-58. PubMed ID: 23061737
[TBL] [Abstract][Full Text] [Related]
3. Comparison of the incidence rates of thromboembolic events reported for patients prescribed celecoxib and meloxicam in general practice in England using Prescription-Event Monitoring (PEM) data.
Layton D; Hughes K; Harris S; Shakir SA
Rheumatology (Oxford); 2003 Nov; 42(11):1354-64. PubMed ID: 12867585
[TBL] [Abstract][Full Text] [Related]
4. Systematic review and meta-analysis on the adverse events of rimonabant treatment: considerations for its potential use in hepatology.
Chavez-Tapia NC; Tellez-Avila FI; Bedogni G; Crocè LS; Masutti F; Tiribelli C
BMC Gastroenterol; 2009 Oct; 9():75. PubMed ID: 19818116
[TBL] [Abstract][Full Text] [Related]
5. Safety and drug utilization profile of varenicline as used in general practice in England: interim results from a prescription-event monitoring study.
Kasliwal R; Wilton LV; Shakir SA
Drug Saf; 2009; 32(6):499-507. PubMed ID: 19459717
[TBL] [Abstract][Full Text] [Related]
6. Feedback and lessons from the prescription of rimonabant, a drug to be used under strict guidelines, in southeastern France, March 2007 through June 2008.
Jardin M; Cortaredona S; Bocquier A; Nauleau S; Sciortino V; Bouvenot J; Sauze L; Bouvenot G; Verger P
Rev Epidemiol Sante Publique; 2011 Apr; 59(2):115-22. PubMed ID: 21435807
[TBL] [Abstract][Full Text] [Related]
7. Comparison of the incidence rates of thromboembolic events reported for patients prescribed rofecoxib and meloxicam in general practice in England using prescription-event monitoring (PEM) data.
Layton D; Heeley E; Hughes K; Shakir SA
Rheumatology (Oxford); 2003 Nov; 42(11):1342-53. PubMed ID: 12832706
[TBL] [Abstract][Full Text] [Related]
8. The psychiatric side-effects of rimonabant.
Moreira FA; Crippa JA
Braz J Psychiatry; 2009 Jun; 31(2):145-53. PubMed ID: 19578688
[TBL] [Abstract][Full Text] [Related]
9. Comparison of the incidence rates of selected gastrointestinal events reported for patients prescribed celecoxib and meloxicam in general practice in England using prescription-event monitoring (PEM) data.
Layton D; Hughes K; Harris S; Shakir SA
Rheumatology (Oxford); 2003 Nov; 42(11):1332-41. PubMed ID: 12810929
[TBL] [Abstract][Full Text] [Related]
10. A comparison of reported gastrointestinal and thromboembolic events between rofecoxib and celecoxib using observational data.
Kasliwal R; Layton D; Harris S; Wilton L; Shakir SA
Drug Saf; 2005; 28(9):803-16. PubMed ID: 16119973
[TBL] [Abstract][Full Text] [Related]
11. A modified prescription-event monitoring study to assess the introduction of Seretide Evohaler in England: an example of studying risk monitoring in pharmacovigilance.
Perrio MJ; Wilton LV; Shakir SA
Drug Saf; 2007; 30(8):681-95. PubMed ID: 17696581
[TBL] [Abstract][Full Text] [Related]
12. [Rimonabant. Risk of depression has not been finally clarified].
Kreutzkamp B
Med Monatsschr Pharm; 2008 May; 31(5):191-2. PubMed ID: 18552079
[No Abstract] [Full Text] [Related]
13. Psychosis following anti-obesity treatment with rimonabant.
Ugur T; Bartels M; Kis B; Scherbaum N
Obes Facts; 2008; 1(2):103-5. PubMed ID: 20054169
[TBL] [Abstract][Full Text] [Related]
14. Cannabinoid type 1 receptor antagonists for smoking cessation.
Cahill K; Ussher MH
Cochrane Database Syst Rev; 2011 Mar; 2011(3):CD005353. PubMed ID: 21412887
[TBL] [Abstract][Full Text] [Related]
15. Incidence of venous thromboembolism in users of strontium ranelate: an analysis of data from a prescription-event monitoring study in England.
Osborne V; Layton D; Perrio M; Wilton L; Shakir SA
Drug Saf; 2010 Jul; 33(7):579-91. PubMed ID: 20553059
[TBL] [Abstract][Full Text] [Related]
16. Use of atomoxetine and suicidal ideation in children and adolescents: Results of an observational cohort study within general practice in England.
Davies M; Coughtrie A; Layton D; Shakir SA
Eur Psychiatry; 2017 Jan; 39():11-16. PubMed ID: 27810613
[TBL] [Abstract][Full Text] [Related]
17. Monitoring the safety of pioglitazone : results of a prescription-event monitoring study of 12,772 patients in England.
Kasliwal R; Wilton LV; Shakir SA
Drug Saf; 2008; 31(10):839-50. PubMed ID: 18759508
[TBL] [Abstract][Full Text] [Related]
18. Safety profile of celecoxib as used in general practice in England: results of a prescription-event monitoring study.
Layton D; Wilton LV; Shakir SA
Eur J Clin Pharmacol; 2004 Sep; 60(7):489-501. PubMed ID: 15278327
[TBL] [Abstract][Full Text] [Related]
19. Efficacy and safety of the weight-loss drug rimonabant: a meta-analysis of randomised trials.
Christensen R; Kristensen PK; Bartels EM; Bliddal H; Astrup A
Lancet; 2007 Nov; 370(9600):1706-13. PubMed ID: 18022033
[TBL] [Abstract][Full Text] [Related]
20. [Pharmacological therapy of obesity].
Pagotto U; Vanuzzo D; Vicennati V; Pasquali R
G Ital Cardiol (Rome); 2008 Apr; 9(4 Suppl 1):83S-93S. PubMed ID: 18773755
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
